WordNet

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 小児における慢性下痢の原因の概要 overview of the causes of chronic diarrhea in children
2. 先進国の小児における慢性下痢症の診断へのアプローチ approach to the diagnosis of chronic diarrhea in children in developed countries
3. 先進国の成人における慢性下痢に対するアプローチ approach to the adult with chronic diarrhea in developed countries
4. 先進国の成人における急性下痢に対するアプローチ approach to the adult with acute diarrhea in developed countries
5. 発展途上国における成人の急性下痢に対するアプローチ approach to the adult with acute diarrhea in developing countries

Ethnobotanical investigations on plants used in folk medicine in the regions of Constantine and Mila (Northeast of Algeria).

Ouelbani R1, Bensari S2, Mouas TN3, Khelifi D4.
Journal of ethnopharmacology.J Ethnopharmacol.2016 Aug 31. pii: S0378-8741(16)30541-4. doi: 10.1016/j.jep.2016.08.016. [Epub ahead of print]
ETHNO-PHARMACOLOGICAL RELEVANCE: Constantine and Mila regions have been investigated in an ethnobotanical study for the first time. A total of 102 medicinal plants have been cited to treat human ailments. Twenty-eight new species of 31 common plants with 151 new therapeutic applications and 12 new c
PMID 27592312

A review on the elemental contents of Pakistani medicinal plants: Implications for folk medicines.

Aziz MA1, Adnan M2, Begum S3, Azizullah A1, Nazir R4, Iram S3.
Journal of ethnopharmacology.J Ethnopharmacol.2016 Jul 21;188:177-92. doi: 10.1016/j.jep.2016.05.011. Epub 2016 May 10.
ETHNOPHARMACOLOGICAL RELEVANCE: Substantially, plants produce chemicals such as primary and secondary metabolites, which have significant applications in modern therapy. Indigenous people mostly rely on traditional medicines derived from medicinal plants. These plants have the capacity to absorb a v
PMID 27174080

Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.

Kong A1,2, Rea D2, Ahmed S3, Beck JT4, López RL5, Biganzoli L6, Armstrong AC7, Aglietta M8, Alba E9, Campone M10, Schmitz SH11, Lefebvre C12, Akimov M13, Lee SC14.
Oncotarget.Oncotarget.2016 Apr 25. doi: 10.18632/oncotarget.8974. [Epub ahead of print]
This open-label, multicenter, phase 1B/2 trial assessed AUY922 plus trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer previously treated with chemotherapy and anti-HER2 therapy. This study was composed of a dose-escalation part with AUY922 administered weekly at
PMID 27129177